LBP-008: SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis pati

Journal of Viral Hepatitis ◽

10.1111/jvh.13_12935 ◽

2018 ◽

Vol 25 ◽

pp. 198-199

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Phase 3 ◽

Multicenter Phase

Download Full-text

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

10.1002/hep.29541 ◽

2018 ◽

Vol 67 (2) ◽

pp. 514-523 ◽

Author(s):

David Wyles ◽

Fred Poordad ◽

Stanley Wang ◽

Laurent Alric ◽

Franco Felizarta ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Prior Treatment ◽

Virus Genotype ◽

Phase 3 ◽

Treatment Experience

Download Full-text

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.02.028 ◽

2021 ◽

Vol 105 ◽

pp. 686-687

Author(s):

Zarir F. Udwadia ◽

Hanmant Barkate ◽

Saiprasad Patil ◽

Shabbir Rangwala ◽

Wen Wu ◽

...

Keyword(s):

Clinical Trial ◽

Rna Polymerase ◽

Efficacy And Safety ◽

Rna Dependent Rna Polymerase ◽

Phase 3 ◽

Multicenter Phase ◽

Polymerase Inhibitor

Download Full-text

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2020.11.142 ◽

2021 ◽

Vol 103 ◽

pp. 62-71 ◽

Author(s):

Zarir F. Udwadia ◽

Pawan Singh ◽

Hanmant Barkate ◽

Saiprasad Patil ◽

Shabbir Rangwala ◽

...

Keyword(s):

Clinical Trial ◽

Rna Polymerase ◽

Efficacy And Safety ◽

Rna Dependent Rna Polymerase ◽

Phase 3 ◽

Multicenter Phase ◽

Polymerase Inhibitor

Download Full-text

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype

Blood Coagulation & Fibrinolysis ◽

10.1097/mbc.0000000000000638 ◽

2017 ◽

Vol 28 (7) ◽

pp. 540-550 ◽

Author(s):

Frank Driessler ◽

Maricel G. Miguelino ◽

Glenn F. Pierce ◽

Robert T. Peters ◽

Jurg M. Sommer

Keyword(s):

Clinical Trial ◽

Factor Viii ◽

Recombinant Factor Viii ◽

Phase 3 ◽

Multicenter Phase

Download Full-text

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2021.02.035 ◽

2021 ◽

Vol 105 ◽

pp. 722

Author(s):

Mahender Kumar Medisetty ◽

Atul Patel ◽

Sanjay Pujari

Keyword(s):

Clinical Trial ◽

Rna Polymerase ◽

Efficacy And Safety ◽

Rna Dependent Rna Polymerase ◽

Phase 3 ◽

Multicenter Phase ◽

Letter To The Editor ◽

Polymerase Inhibitor

Download Full-text

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

10.26226/morressier.5aeaf2d35800a00019097f85 ◽

2018 ◽

Author(s):

Christian Wisskirchen ◽

Hans-Jürgen Stellbrink

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination ◽

Download Full-text

The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Case Medical Research ◽

10.31525/ct1-nct04207736 ◽

2019 ◽

Author(s):

Keyword(s):

Clinical Trial ◽

Allergic Conjunctivitis ◽

Crossover Design ◽

Design Phase ◽

Efficacy And Safety ◽

Phase 3 ◽

Seasonal Allergic Conjunctivitis

Download Full-text

Faculty of 1000 evaluation for Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717965604.793466618 ◽

2012 ◽

Author(s):

Alex Thompson

Keyword(s):

Clinical Trial ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Randomised Clinical Trial ◽

Combination Regimen ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718087883.793484663 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Randomized Clinical Trial ◽

Treatment Characteristics

Download Full-text

Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725431366.793505980 ◽

2015 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

Previously Treated

Download Full-text